Skip to content
Sign in
SWC 2026 Top 10

BioSapien

3D-printed biodegradable MediChip implant delivering chemotherapy locally at the tumour site, now in colorectal cancer trials in the UAE.

Abu Dhabi, United Arab Emirates, Middle EastBiotech & life sciences, Oncology – local drug deliverySilicon Valley Regional 2026 (champion)
Stage
SeedNo documented AI
Product
PilotPilots / LOIs
Funding raised
$8.3Mdisclosed
Founded
20188 years ago
Founders
1Khatija
Global score
4.5Grade DRank 63 of 151

Overview

BioSapien develops MediChip™, a platform for localized, extended-release delivery of cancer drugs, implanted directly against the tumor or tissue. Clinical trials in colorectal cancer are being conducted in the United Arab Emirates.

Traction

Pilots / LOIs

MediChip in clinical trials for colorectal cancer in the UAE; no sales yet (pre-Series A round of more than $8M).

Market

Implantable drug delivery devices

Local drug delivery targets a structural limit of oncology: systemic chemotherapy exposes the whole body to toxicity while delivering only a fraction of the dose to the tumour. Buyers are hospitals and surgical oncology teams, but value is realised through regulatory approval and reimbursement, typically with a pharma or device partner. Gulf governments are actively funding life-science companies and trials, which explains BioSapien's Abu Dhabi base. The model is a long, binary clinical path before any revenue.

Addressable market

2025
$16.2B
2030
$21.9B
+6.25% a year

Implantable drug delivery devices: $16.2bn in 2025, +6.3%/year (IMARC); the local oncology niche is a fraction of it.

Customers

Surgical oncology and colorectal cancer centres; pharma companies seeking new delivery formats for approved cytotoxics.

Who signs the cheque

Hospital oncology departments (post-approval, via reimbursement); pharma business development teams (licensing/co-development).

Geographies

  • United Arab Emirates
  • Gulf Cooperation Council
  • United States (NSF-funded R&D)

Drivers

  • Toxicity of systemic chemotherapy and demand for localised, sustained dosing
  • Maturity of medical 3D printing and biodegradable polymers
  • Gulf state investment in life sciences and local clinical trials

Headwinds

  • Drug-device combination regulatory pathway, country by country
  • Capital needs (over $8M raised) far below the cost of pivotal trials
  • No efficacy data published yet

The implantable drug delivery devices market reaches $16.2bn in 2025 (+6.3%/year, $28bn in 2034) according to IMARC; estimates range from $16–23bn, and the local oncology niche is a fraction of it.

Scalability 5/10. Implantable device platform exportable once approved, but country-by-country approval and long clinical trials.

Market source: imarcgroup.com

Technology

Category

Drug-device combination (implantable drug delivery)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

MediChip is a 3D-printed, biodegradable implant attached directly to the tumour or tissue that releases a cancer drug slowly over time. The design aims at high local exposure with fewer systemic side effects.

Moat

Potentially strong once clinical data exist: platform know-how in printing, polymer degradation and release kinetics plus clinical evidence and regulatory files. The patent position is not documented in the record, so current defensibility rests on being in the clinic first.

Differentiation

Versus systemic IV chemotherapy, delivers drug at the tumour with lower systemic exposure; versus generic intratumoral injections, provides extended release from an implant attachable to any tissue.

Integration points

  • Surgical resection workflows
  • Pharma pipelines of approved cytotoxics (reformulation)
  • Oncology trial site networks
  • Real-world oncology datasets for trial design

Depends on

  • Drug-device combination approvals (UAE, then FDA/EMA)
  • Licensing or supply of the incorporated cytotoxic drug
  • GMP-grade 3D printing and biodegradable polymer supply

Use of AI

No use of AI mentioned

Product in detail

3D-printed, biodegradable, slow-release implant that can be attached to any tissue, enabling local chemotherapy with fewer systemic side effects.

Business

Model
Pre-revenue; likely licensing/co-development with pharma and device sales after approval (not disclosed).
Revenue logic
Unknown; a combination product would typically be priced per implant and reimbursed as a procedure add-on.
Go-to-market
Clinical development in the UAE, investor-led introductions (Global Ventures, Golden Gate Ventures) and partnering with pharma once interim data exist.

Next milestones

  1. Interim safety/efficacy readout from the colorectal trial
  2. US IND or equivalent filing to open a second jurisdiction
  3. First pharma co-development or licensing agreement

Key risks

  • Clinical failure or safety signal in the colorectal trial
  • Regulatory complexity of combination products
  • Financing gap before pivotal trials

Opportunities

4 found in the network

Concrete moves for BioSapien inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Co-development 2
  • Investors 1

Customers1

Who could buy, or sell through

Buy oncology real-world data to design the next trial

BioSapien must choose indications, endpoints and sites for its next trials. Cromodata sells de-identified, standardised oncology and imaging datasets from a network of hospitals in five Latin American countries, which can inform recurrence rates and control-arm assumptions and identify candidate trial sites outside the UAE.

30%confidence

Evidence from the records

  • “Clinical trials in colorectal cancer are being conducted in the United Arab Emirates.”
  • “Pipeline for de-identifying and standardizing fragmented clinical records (imaging, oncology) into usable datasets, with secure access.”
If it works
Better-powered trial design and a shortlist of Latin American sites; a named pharma-grade data buyer for Cromodata.
First step
Send Cromodata a data request for colorectal cancer cohorts (surgery, recurrence, chemotherapy regimens) and request a sample dictionary.

Co-development2

An integration or joint product

Polymer platform partnership for next-generation implants

MediChip's performance depends on polymer degradation and release kinetics; Pleryon has proprietary platforms to design and control large synthetic and modified natural polymers for drug delivery and injectable biomaterials. A material-supply or joint-development agreement could extend MediChip's release window or open injectable formats, while giving Pleryon an oncology application outside ophthalmology.

30%confidence

Evidence from the records

  • “3D-printed, biodegradable, slow-release implant that can be attached to any tissue”
  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
If it works
A jointly owned next-generation MediChip formulation and a stronger IP position for both companies.
First step
Hold a CSO-to-CSO call to compare polymer requirements (degradation time, drug loading) against Pleryon's catalogue.

Simulate implant release kinetics before printing

Each formulation iteration of an implant costs months of bench work. Caldera Engine couples physics simulation of macromolecular suspensions with AI to predict material properties; applied to MediChip's polymer-drug matrix it could narrow formulation candidates before wet-lab testing.

20%confidence

Evidence from the records

  • “slow-release implant”
  • “Caldera Engine: physics simulation of macromolecular suspensions coupled with AI to predict material properties.”
If it works
Shorter formulation cycles for MediChip variants and a first published life-science customer for Monte Caldera.
First step
Request a Caldera Engine trial and share one non-confidential polymer formulation for a feasibility simulation.

Investors1

A fund whose thesis fits

Approach a science-first VC for the Series A

BioSapien's next round must fund clinical progress; Breakout backs founders pairing technology with science at Seed and Series A and has a US focus consistent with BioSapien's NSF-funded R&D and Silicon Valley regional win. Breakout led ZymoChem's Series A, offering a warm introduction inside the network.

30%confidence

Evidence from the records

  • “Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).”
  • “Breakout Ventures (lead), lululemon, Toyota Ventures, GS Futures, KdT Ventures, Cavallo Ventures”
  • “grant (NSF)”
If it works
A US science-focused co-investor that would de-risk an FDA pathway for MediChip.
First step
Ask ZymoChem's CEO for an introduction to the Breakout partner on his board, with a two-page clinical plan attached.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Abu Dhabi tech ecosystem backed by the Government and Mubadala, offering startups up to ~$204K in cash and in-kind incentives.

UAE oncology drug delivery, already UAE-based — Hub71's incentives and Mubadala ecosystem fit a regulated health company.

50%confidence

Evidence from the records

  • “Mubadala”
  • “Oncology – local drug delivery”
  • “MediChip in clinical trials for colorectal cancer in the UAE”
First step
Ask Global Ventures (BioSapien lead) for a Hub71 introduction.

Pioneer MENA VC (>$300M AUM, $150M Fund IV) backing early- and growth-stage tech across MENA, Pakistan and Turkey with an ESG lens.

UAE oncology drug delivery — MENA health; more biotech than MEVP's usual software.

40%confidence

Evidence from the records

  • “"HealthTech"”
  • “Oncology – local drug delivery”
  • “MediChip in clinical trials for colorectal cancer in the UAE”

Shenzhen life-science investor (since 2012) backing drug developers with phase 2/3 assets and device makers; backed Pleryon Therapeutics.

Oncology local drug delivery in clinical trials in the UAE with an $8M+ pre-Series A: clinical-stage drug-device combination.

40%confidence

Evidence from the records

  • “Oncology – local drug delivery”
  • “MediChip in clinical trials for colorectal cancer in the UAE”
First step
Share trial readouts and China development plan.

Dubai VC with $820M AUM backing Gulf-rooted tech founders from pre-seed to IPO in the UAE and Saudi Arabia (Careem, Kitopi).

UAE oncology drug-delivery with trials in the UAE and an $8M+ pre-Series A: Gulf-based, but biotech is outside BECO's sectors.

15%confidence

Evidence from the records

  • “Oncology – local drug delivery”
  • “United Arab Emirates”
Intro path
Global Ventures (BioSapien investor, Dubai)
First step
Low priority.

Investment analysis

4.5D

Grade D

Rank 63 of 151

Disruption7.0/10
Business model3.0/10
Market5.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

High-potential but binary biotech bet, to consider only with interim clinical data.

Disruption

7/10

MediChip, an implant for local, extended delivery of cancer drugs, is a new approach that could change oncology practice.

Business model

3/10

No sales: clinical trials in colorectal cancer under way; the model remains to be proven.

Market

5/10

TAM $16.2bn → base 5; scalability 5/10 (neutral); no international presence: no sales, trials in the UAE only → 5/10.

Risk

8/10

Lower is better

High risk: clinical, regulatory (drug-device) and financial, with only $8M for a long approval pathway.

Strengths

  • Differentiated therapeutic approach
  • Clinical trials already under way

Risks

  • Major clinical and regulatory risk
  • Capital needs far above funds raised

Funding

$8.3M, disclosed
  1. déc. 2024

    pre-Series A$5.5M (AED 20.2M)

    Global Ventures (lead), Dara Holdings

  2. janv. 2025

    pre-Series A extensionraised to $7M

    Golden Gate Ventures (among others)

  3. juil. 2025

    pre-Series A extensionraised to more than $8M

    Globivest, Global Talent

  4. n.d.

    grant (NSF)$256,000

    National Science Foundation (US)

Amount used in the study. Pre-Series A extended to more than $8M (the final amount includes the earlier tranches) + $256k NSF grant; outdated $2.5M figure ignored.

Note. More than $8M (extended pre-Series A) + $256,000 NSF grant (according to known data); a CEO Review article cites $2.5M (probably outdated)

verified, nothing to correct: winner of the Silicon Valley regional (7 May 2026) confirmed by Business Wire; latest round = pre-Series A extension to >$8M (July 2025, Globivest); no 2026 Series A found.

Team

  • Khatija Ali

    Founder & CEO

    Founder of BioSapien (2017/2018); named Abu Dhabi's "Most Influential CEO 2025" in drug delivery innovation.

Sources

Regional final
Silicon Valley Regional 2026 (champion)
Identification confidence
high
Founding year: 2018 (high confidence)
Founding year (Khatija Ali) according to Hub71, Wamda and CB Insights; sources agree. Headquarters sometimes listed in California (San Diego), operations in Abu Dhabi. wamda.com
  1. 1biosapien.com/
  2. 2businesswire.com/news/home/20260609019952/en/BioSapien-Wins-2026-Startup-Wor
  3. 3wamda.com/index.php/2024/12/uae-based-biotech-biosapien-secures-5-5-m
  4. 4wamda.com/en/2025/01/biosapien-extends-pre-series-a-round-7-million
  5. 5wamda.com/index.php/2025/07/biosapien-extends-pre-series-a-8-million-

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet